DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.89

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.09M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.05 (+0.05%)

USD 17.69B
IVV:AU iShares Core S&P 500 AUD

+0.60 (+0.95%)

USD 11.11B
VGS:AU Vanguard MSCI International Sh..

+1.20 (+0.86%)

USD 10.01B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.28 (+0.48%)

USD 7.21B
IOZ:AU Ishares Core S&P/Asx 200

-0.04 (-0.12%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

+0.01 (+0.01%)

USD 5.69B
VTS:AU Vanguard US Total Market Share..

+4.73 (+1.01%)

USD 5.38B
NDQ:AU Betashares Nasdaq 100

+0.69 (+1.37%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.53 (+1.25%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.04 (+0.03%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.38% 72% C 50% F
Dividend Return 0.35% 16% F 15% F
Total Return 0.73% 69% C- 52% F
Trailing 12 Months  
Capital Gain -2.95% 8% B- 51% F
Dividend Return 3.08% 42% F 34% F
Total Return 0.13% 8% B- 50% F
Trailing 5 Years  
Capital Gain 19.00% 62% D 70% C-
Dividend Return 11.04% 27% F 27% F
Total Return 30.04% 50% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.99% 69% C- 55% F
Dividend Return 8.65% 67% D+ 54% F
Total Return 1.65% 58% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 8.44% 65% D 92% A
Risk Adjusted Return 102.44% 94% A 97% N/A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.